AB0652 Thrombin Activated Fibrinolysis Inhibitors (TAFI) Levels in Active Diffuse Systemic Sclerosis Patients

Background Thrombin-activated fibrinolysis inhibitors (TAFI) is activated by the endothelial surface thrombin and has an important role on the relation of coagulation, fibrinolysis and inflammatory systems. Basically, activation of TAFI down-regulates fibrinolysis and also, leads the neutrophil activation triggered by C5 and kinin related inflammatory systems. Objectives We aimed to show the relation between the serum TAFI levels and disease activity of diffuse systemic sclerosis patients (SSc). Methods 13 active SSc female patients with interstitial lung disease and 10 healthy women were involved in to the study. From the serum samples of both groups, TAFI levels were measured by ELISA method using pefakit TAFI (Penthafarm, Basel). Results Serum TAFI levels of SSc patients was 63.1±19.1 mg/dL SD (min-max: 30-90 mg/dL) and control group9s TAFI level was 41.0±11.1mg/dL SD (min-max: 9-59 mg/dL). All data was analysed by Mann-Whitney U test. P Conclusions Fibrinolytic activity is linked to inflammation. Increased amount of TAFI in serum may explain why fibrin formation is so prominent in SSc. And also TAFI may play important roles in the mechanism of intraalveolar hypofibrinolysis associated with interstitial lung disease. References MJ Peters. Ann Rheum Dis 2009; 68(7):1232-3. Ringwald J. Throm Res 2002; 119(1):129-31. Sak S. J Throm Haemost 2003; Dec;1(12): 2510-5. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4853